Long-Term Benefits of INGREZZA for Older Adults
A recent analysis published in a prestigious journal provides significant insights into the long-term effectiveness of INGREZZA® (valbenazine) capsules for older adults suffering from tardive dyskinesia (TD). This analysis specifically reflects on individuals aged 65 and older and underscores the compelling improvements seen in symptoms without introducing new adverse side effects.
Key Findings of the Study
The post-hoc analysis examined data from two comprehensive studies, KINECT® 3 and KINECT® 4, focusing on patients over an extended period. These studies revealed that participants showed remarkable and sustained improvements in their TD symptoms when treated with INGREZZA, marking it as the first peer-reviewed study of its kind specifically addressing this vulnerable population;
Dr. Eiry W. Roberts, Chief Medical Officer at Neurocrine Biosciences, emphasized the importance of this analysis, noting that older patients achieved significant improvements just eight weeks into treatment. Such results continue to show lasting benefits over the full 48 weeks of treatment, reinforcing the suitability of INGREZZA for older adults.
Methodology of the Analysis
The analysis included over 300 participants, with a noteworthy portion being older adults aged 65 and above. Participants were administered daily doses of either 40 mg or 80 mg of INGREZZA about a year-long treatment period. Key metrics for evaluating efficacy included improvement rates on the Abnormal Involuntary Movement Scale (AIMS), among other assessments. Remarkably, data highlighted that 95% of participants on the higher dose demonstrated significant thresholds in symptom alleviation.
Notably, the safety profile remained stable and well-tolerated, with common side effects such as urinary tract infection and drowsiness reported among the older demographic. Importantly, there were no significant differences in efficacy and safety outcomes when comparing this age group to younger adults.
Implications for the Treatment of Tardive Dyskinesia
Tardive dyskinesia is a serious movement disorder, often stemming from medications prescribed for mental health conditions. Older adults are often particularly susceptible due to prolonged exposure to antipsychotics. The uncontrolled movements associated with TD can drastically affect their quality of life, leading to risks including falls and swallowing difficulties.
Indeed, this analysis provides crucial data supporting the use of INGREZZA in treating this persistent disorder among older individuals, allowing healthcare providers to make more informed decisions regarding their older patients' treatment options.
Innovations in INGREZZA Treatment
INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that is unique in its formulation. It offers a therapeutic dose from the first day without the necessity for titration. This means older patients and those with swallowing difficulties can achieve effective management of TD symptoms with ease.
Broader Impact on Neurocrine Biosciences' Mission
Neurocrine Biosciences continues to aim high with its commitment to advancing treatments for under-addressed neurological disorders. With a diverse portfolio that includes therapies for both TD and Huntington’s disease, the company is dedicated to improving the quality of life for patients across a range of conditions.
Frequently Asked Questions
What is INGREZZA used for?
INGREZZA is prescribed for adults with tardive dyskinesia and chorea associated with Huntington's disease.
How does INGREZZA work?
It selectively inhibits the VMAT2 transporter in the brain to manage motor control and reduce involuntary movements.
What were the main findings from the study?
The study revealed significant and consistent efficacy in alleviating TD symptoms in older adults without introducing new adverse side effects.
How long does treatment with INGREZZA last?
The analyzed studies were conducted over a period of 48 weeks, demonstrating sustained treatment benefits.
How is INGREZZA administered?
INGREZZA is taken as a capsule, with daily doses typically of 40 mg or 80 mg, as indicated by a healthcare professional.
